Definium Therapeutics (NASDAQ:DFTX) CEO Sells $1,153,783.50 in Stock

Posted by Geri Gentry on Oct 2nd, 2026

Definium Therapeutics, Inc. (NASDAQ:DFTX – Get Free Report) CEO Robert Barrow sold 31,550 shares of Definium Therapeutics stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $1,153,783.50. Following the completion of the transaction, the chief executive officer directly owned 2,213,090 shares in the company, valued at approximately $80,932,701.30. The trade was a 1.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Barrow also recently made the following trade(s):

On Thursday, September 3rd, Robert Barrow sold 19,023 shares of Definium Therapeutics stock. The shares were sold at an average price of $37.94, for a total transaction of $721,732.62.

Definium Therapeutics Trading Down 1.2%

Shares of DFTX opened at $37.60 on Friday. The stock has a market capitalization of $5.05 billion, a P/E ratio of -10.96 and a beta of 2.19. Definium Therapeutics, Inc. has a twelve month low of $10.46 and a twelve month high of $49.70. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The firm has a fifty day simple moving average of $41.15 and a two-hundred day simple moving average of $32.34.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, research analysts anticipate that Definium Therapeutics, Inc. will post -3.02 EPS for the current year.

Hedge Funds Weigh In On Definium Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nykredit A S bought a new position in Definium Therapeutics in the second quarter worth about $45,000. Allworth Financial LP bought a new stake in Definium Therapeutics during the 2nd quarter valued at approximately $110,000. Integrated Wealth Concepts LLC purchased a new position in shares of Definium Therapeutics during the 2nd quarter worth approximately $159,000. NewEdge Advisors LLC purchased a new position in shares of Definium Therapeutics during the 2nd quarter worth approximately $222,000. Finally, WINTON GROUP Ltd purchased a new position in shares of Definium Therapeutics during the 2nd quarter worth approximately $240,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Wall Street Zen downgraded Definium Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Needham & Company LLC reiterated a “buy” rating and issued a $66.00 price objective on shares of Definium Therapeutics in a report on Monday, September 14th. Canaccord Genuity Group set a $78.00 price objective on Definium Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, September 15th. Piper Sandler reiterated an “overweight” rating and issued a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a research report on Friday, August 7th. Finally, Bank of America began coverage on Definium Therapeutics in a research note on Tuesday, August 18th. They set a “buy” rating and a $75.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $64.88.

View Our Latest Analysis on DFTX

Definium Therapeutics Company Profile

(Get Free Report)

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.